 | • レポートコード：MRC2304D142 • 出版社/出版日：Transparency Market Research / 2023年1月25日 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、虚血再灌流障害治療薬の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療法別（薬物療法、薬用ガス、その他）分析、 傷害種類別（心臓損傷、腎臓損傷、腸損傷、その他）分析、エンドユーザー別（病院、専門クリニック、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況などを収録しています。また、Amyndas Pharmaceuticals LLC、Angion、Bolder Biotechnology、Opsona Therapeutics Ltd.、Pharming Group NV、Prolong Pharmaceuticals、Prothix BV、Stealth BioTherapeutics, Inc.、Zealand Pharma A/S、Faraday Pharmaceuticals、SBI Pharmaceuticalsなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の虚血再灌流障害治療薬市場規模：治療法別 - 薬物療法の市場規模 - 薬用ガス治療の市場規模 - その他治療法の市場規模 ・世界の虚血再灌流障害治療薬市場規模：傷害種類別 - 心臓損傷における市場規模 - 腎臓損傷における市場規模 - 腸損傷における市場規模 - その他傷害種類における市場規模 ・世界の虚血再灌流障害治療薬市場規模：エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の虚血再灌流障害治療薬市場規模：地域別 - 北米の虚血再灌流障害治療薬市場規模 - ヨーロッパの虚血再灌流障害治療薬市場規模 - アジア太平洋の虚血再灌流障害治療薬市場規模 - 中東・アフリカの虚血再灌流障害治療薬市場規模 - 南米の虚血再灌流障害治療薬市場規模 ・競争状況 |
Ischemia Reperfusion Injury Therapeutics Market – Scope of Report
TMR’s report on the global ischemia reperfusion injury therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ischemia reperfusion injury therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ischemia reperfusion injury therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ischemia reperfusion injury therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ischemia reperfusion injury therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ischemia reperfusion injury therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ischemia reperfusion injury therapeutics market.
The report delves into the competitive landscape of the global ischemia reperfusion injury therapeutics market. Key players operating in the global ischemia reperfusion injury therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ischemia reperfusion injury therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ischemia reperfusion injury therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ischemia Reperfusion Injury Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Development
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. COVID 19 Impact on Industry
6. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2031
6.3.1. Drug Therapy
6.3.2. Medicated Gases
6.3.3. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Injury Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Injury Type, 2017–2031
7.3.1. Heart Injury
7.3.2. Kidney Injury
7.3.3. Intestine Injury
7.3.4. Others
7.4. Market Attractiveness Analysis, by Injury Type
8. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2031
10.2.1. Drug Therapy
10.2.2. Medicated Gases
10.2.3. Others
10.3. Market Value Forecast, by Injury Type, 2017–2031
10.3.1. Heart Injury
10.3.2. Kidney Injury
10.3.3. Intestine Injury
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Injury Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2031
11.2.1. Drug Therapy
11.2.2. Medicated Gases
11.2.3. Others
11.3. Market Value Forecast, by Injury Type, 2017–2031
11.3.1. Heart Injury
11.3.2. Kidney Injury
11.3.3. Intestine Injury
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Injury Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2031
12.2.1. Drug Therapy
12.2.2. Medicated Gases
12.2.3. Others
12.3. Market Value Forecast, by Injury Type, 2017–2031
12.3.1. Heart Injury
12.3.2. Kidney Injury
12.3.3. Intestine Injury
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Injury Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2031
13.2.1. Drug Therapy
13.2.2. Medicated Gases
13.2.3. Others
13.3. Market Value Forecast, by Injury Type, 2017–2031
13.3.1. Heart Injury
13.3.2. Kidney Injury
13.3.3. Intestine Injury
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Injury Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017–2031
14.2.1. Drug Therapy
14.2.2. Medicated Gases
14.2.3. Others
14.3. Market Value Forecast, by Injury Type, 2017–2031
14.3.1. Heart Injury
14.3.2. Kidney Injury
14.3.3. Intestine Injury
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment
14.6.2. By Injury Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amyndas Pharmaceuticals LLC
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Angion
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Bolder Biotechnology
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Opsona Therapeutics Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Pharming Group NV
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Prolong Pharmaceuticals
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Prothix BV
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Stealth BioTherapeutics, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Zealand Pharma A/S
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. Faraday Pharmaceuticals
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.11. SBI Pharmaceuticals
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview